Literature DB >> 19490487

Domino liver graft from a patient with homozygous familial hypercholesterolemia.

Chinsu Liu1, Dau-Ming Niu, Che-Chuan Loong, Cheng-Yuan Hsia, Mei-Yung Tsou, Hsin-Lin Tsai, Choufu Wei.   

Abstract

HFH is a metabolic disease caused by a defect in the gene that encodes the synthesis of the cellular receptor for LDL-Rs. A high plasma level of cholesterol is present from birth and leads to severe atherosclerosis in childhood, and death from myocardial infarction usually occurs before the age of 20 yr. The liver contains approximately 50-75% of the total body LDL-Rs; therefore, liver transplantation has been carried out to treat this metabolic disorder effectively. The rationale for using an HFH liver for a domino graft is that the absence of functional LDL-Rs in the liver may be compensated for by the extra-hepatic LDL-Rs. Therefore, an HFH liver can possibly be used as a domino graft for a recipient with a normal plasma cholesterol level before transplantation. We herein report a domino liver transplantation using an HFH liver as a domino graft with successful results. To expand the donor pool, especially in Asian countries, domino grafts from HFH should be encouraged by careful selection of the domino recipient.

Entities:  

Mesh:

Year:  2009        PMID: 19490487     DOI: 10.1111/j.1399-3046.2009.01133.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  2 in total

1.  Successful Domino Liver Transplantation from a Patient with Methylmalonic Acidemia.

Authors:  A Khanna; R Gish; S C Winter; W L Nyhan; B A Barshop
Journal:  JIMD Rep       Date:  2015-07-29

2.  Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation.

Authors:  Neslihan Celik; Beau Kelly; Kyle Soltys; James E Squires; Jerry Vockley; Diana A Shellmer; Kevin Strauss; Patrick McKiernan; Armando Ganoza; Rakesh Sindhi; Geoffrey Bond; George Mazariegos; Ajai Khanna
Journal:  Clin Transplant       Date:  2019-10-06       Impact factor: 2.863

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.